Seedlabs

Unexplained Weight-Loss CV Risk Flag

An alert for doctors that flags unexpected weight loss in heart patients as a warning sign for heart attacks.

An electronic health record alert that flags weight loss in overweight heart-disease patients who are not on any weight-loss treatment, prompting doctors to check the heart because spontaneous weight loss in this group signals higher risk of heart attack and stroke.

MedicineDiabetes Treatment and Management
Metabolism and Genetic DisordersEHR clinical decision support for cardiovascular risk detection

Concept

An EHR decision-support module for cardiology and primary care: when a chart shows documented overweight/obesity plus established cardiovascular disease, and a clinically meaningful weight drop is recorded with no active weight-management therapy (no GLP-1, no bariatric program, no documented lifestyle intervention), the chart displays a flag — "Unexplained weight loss in CVD: associated with elevated cardiovascular event risk in trial data" — and prompts a short structured review (angina or heart-failure symptoms, medication changes, appetite, basic labs). The module includes logic to distinguish intentional, therapy-associated loss from spontaneous loss, so the growing number of GLP-1-induced weight losses does not drown the warning signal.

Why now

In the placebo arm of SELECT — roughly half of 17,604 patients with overweight/obesity and established CVD, without diabetes — weight loss was paradoxically associated with increased MACE risk, and baseline bodyweight carried no prognostic information (HR 0.99), while smaller waist circumference did (HR 0.96 per 5 cm). This quantifies, in a modern, well-characterized CVD population, that spontaneous weight loss is a marker of elevated near-term cardiovascular risk rather than a health win. As GLP-1 prescribing makes weight loss routine in medical charts, clinicians increasingly default to reading any loss as success; an explicit flag restores the unintentional-loss warning signal with trial numbers behind it.

Written by GLM · 10 Oct 2026

AI assessment

Backed by 1 paper92

A high-utility, low-complexity EHR alert that leverages a specific trial finding to prevent clinicians from misinterpreting spontaneous weight loss as a positive health indicator in high-risk CVD patients.

Evidence strength
5/5
The idea is directly derived from a prespecified analysis of the SELECT trial, which explicitly found that weight loss in the placebo arm (spontaneous loss) was associated with increased MACE risk.
Market pull
4/5
Health systems like Kaiser Permanente and EHR vendors have a strong incentive to reduce preventable MACE events and improve clinical decision support accuracy.
Novelty & moat
4/5
While other catalog ideas focus on GLP-1 management or kidney risk, this is the first to target the 'paradoxical' risk of spontaneous weight loss in the CVD population.
Feasibility
5/5
The logic relies on existing EHR data (weight, diagnosis codes, and medication lists), making it a straightforward implementation via SMART on FHIR or native EHR alerts.
Wedge clarity
5/5
The wedge is a single, sharp clinical alert for a specific patient cohort (overweight + CVD + unexplained weight loss), avoiding platform bloat.
Simplicity / focus
5/5
The product is a focused decision-support module with one clear trigger and one clear clinical action.

Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Epic Systemscompany

    The dominant U.S. EHR vendor; a packaged decision-support alert for unexplained weight loss in CVD extends its cardiology content library with minimal build effort and clear trial evidence.

  • Kaiser Permanenteorganization

    Integrated delivery system with longitudinal weight data and large cardiovascular registries; the flag can surface at-risk members for outreach, and its research arm can validate alert performance against outcomes.

  • American College of Cardiologyorganization

    Develops clinical decision-support pathways and quality tools for cardiologists; the SELECT placebo-arm quantification gives it evidence to embed a spontaneous-weight-loss prompt in cardiology workflows.

  • Oracle Healthcompany

    EHR vendor seeking differentiated clinical content; a ready-made alert module is low-cost, evidence-backed content for its cardiology customers.

Research it builds on

  1. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
    John Eric Deanfield, Abraham Michael Lincoff, Steven E. Kahn et al. · 2025 · 136 citations
    All ideas from this paper →
Leave feedback
feasibility